Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (657)	5/6/2004 1:17:00 PM
From: zeta1961	Read Replies (1) \| Respond to of 897

>>>ONXX<<<< If you ask me...bay-whatever molecule they are making has to be one of the most overhyped molecules in biocancer today....Yes they are showing up at ASCO.......how can they justify this price when the molecule has shown marginal efficacy? The deal is that raf kinase inhibitors are the rage this year at ASCO....just received my pre-ASCO educational book....1.5 inches thick....this class of compounds is discussed all over the place in just about every major cancer.........maybe I'm talking from the microphone of someone who missed the onxx runup....but I've looked at their studies and nothing about them made me want to put a dime in this company... Rant over, Zeta

To: tuck who wrote (657)	5/6/2004 1:53:35 PM
From: rkrw	Respond to of 897

I liked the part about: "stronger than expected Q1 results" and "stock can cont to move as long as clinical data are good." Very insightful :-)

To: tuck who wrote (657)	5/6/2004 7:41:17 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 897

Stock and few analysts are acting like open/randomized-blind PII in CRC will be sufficient for NDA. Even with continuous strong data FDA would not look at NDA until there are survival results in controlled settings, imo. And this is at least 2.5-3.0 years away (to complete trial and submit NDA). I was once short, now just looking for right moment. Miljenko

To: tuck who wrote (657)	5/20/2004 8:25:47 PM
From: Miljenko Zuanic	Respond to of 897

">>10:33AM Onyx Pharma target raised to $66 from $40 at JMP (ONXX) 56.12 +0.83: JMP Securities maintains their Outperform on ONXX and raises their target to $66 from $40 following stronger than expected Q1 results; while the stock's valuation is hardly a bargain, firm believes that it is not out of line with other biotech co's with high-quality products in pivotal trials and near registration; firm views ONXX's lead compound BAY 43-9006 as one of the most exciting compounds in the collective pipeline of the biotech and pharma industries, and believes that the stock can continue to move upward as long as clinical data are good.<<" What are the bad news?